Cargando…

Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors

Activation of the PI3K/AKT pathway occurs in the vast majority of advanced prostate cancers (PCas). Activation of fibroblast growth factor receptor (FGFR) signaling occurs in a wide variety of malignancies, including PCa. RNA-Seq of castration resistant PCa revealed expression of multiple FGFR signa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Shu, Shao, Longjiang, Castro, Patricia, Coleman, Ilsa, Nelson, Peter S, Smith, Paul D, Davies, Barry R, Ittmann, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351622/ https://www.ncbi.nlm.nih.gov/pubmed/28008155 http://dx.doi.org/10.18632/oncotarget.14049

Ejemplares similares

FGF23 promotes prostate cancer progression
por: Feng, Shu, et al.
Publicado: (2015)

Prostate Cancer Cells Are Sensitive to Lysosomotropic Agent Siramesine through Generation Reactive Oxygen Species and in Combination with Tyrosine Kinase Inhibitors
por: Garcia, Emily A., et al.
Publicado: (2022)

Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis
por: Zhang, Li, et al.
Publicado: (2015)

miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer
por: Karatas, Omer Faruk, et al.
Publicado: (2017)

Fibroblast growth factor receptor signaling plays a key role in transformation induced by the TMPRSS2/ERG fusion gene and decreased PTEN
por: Shao, Longjiang, et al.
Publicado: (2018)

Genetic background influences murine prostate gene expression: implications for cancer phenotypes
por: Bianchi-Frias, Daniella, et al.
Publicado: (2007)

The Effects of Aging on the Molecular and Cellular Composition of the Prostate Microenvironment
por: Bianchi-Frias, Daniella, et al.
Publicado: (2010)

DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance
por: Huber, Roland M., et al.
Publicado: (2014)

Single cell transcriptomic analysis of prostate cancer cells
por: Welty, Christopher J, et al.
Publicado: (2013)

Upregulated insulin receptor tyrosine kinase substrate promotes the proliferation of colorectal cancer cells via the bFGF/AKT signaling pathway
por: Wang, Song, et al.
Publicado: (2020)

Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
por: Gao, Lina, et al.
Publicado: (2013)

Constitutive and Regulated Shedding of Soluble FGF Receptors Releases Biologically Active Inhibitors of FGF-2
por: Hanneken, Anne, et al.
Publicado: (2021)

Role of androgen receptor splice variant 7 (AR-V7) in prostate cancer resistance to 2(nd) generation androgen receptor signaling inhibitors
por: Zhu, Yezi, et al.
Publicado: (2020)

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer
por: Qi, Wenqing, et al.
Publicado: (2009)

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
por: Dunn, Shanade, et al.
Publicado: (2022)

A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models()()
por: Mamouni, Kenza, et al.
Publicado: (2018)

MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
por: Clegg, Nicola J., et al.
Publicado: (2011)

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
por: Nghiem, Belinda, et al.
Publicado: (2016)

Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations
por: Patel, Radhika A., et al.
Publicado: (2022)

Overview of the Development and Use of Akt Inhibitors in Prostate Cancer
por: Gasmi, Anis, et al.
Publicado: (2021)

FGF21 facilitates autophagy in prostate cancer cells by inhibiting the PI3K–Akt–mTOR signaling pathway
por: Dai, Han, et al.
Publicado: (2021)

IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR
por: Rojas, Andres, et al.
Publicado: (2011)

Gatekeeper mutations activate FGF receptor tyrosine kinases by destabilizing the autoinhibited state
por: Besch, Alida, et al.
Publicado: (2023)

Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature
por: Labrecque, Mark P., et al.
Publicado: (2021)

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
por: Smyth, Lillian M., et al.
Publicado: (2021)

Doxycycline Regulated Induction of AKT in Murine Prostate Drives Proliferation Independently of p27 Cyclin Dependent Kinase Inhibitor Downregulation
por: Wang, Hongyun, et al.
Publicado: (2012)

Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy
por: Ruppender, Nazanin, et al.
Publicado: (2015)

Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
por: Coleman, Ilsa M., et al.
Publicado: (2022)

The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma
por: Kanzaki, Hiroaki, et al.
Publicado: (2021)

A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors
por: Qu, Xiaoyu, et al.
Publicado: (2013)

Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
por: Dumble, Melissa, et al.
Publicado: (2014)

Durability of and role of AKT in FGF7p urothelial protection against cyclophosphamide
por: Narla, Sridhar Tatarao, et al.
Publicado: (2022)

Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms
por: Bjune, Katrine, et al.
Publicado: (2019)

Upregulation of Receptor Tyrosine Kinase Activity and Stemness as Resistance Mechanisms to Akt Inhibitors in Breast Cancer
por: Tsang, Tiffany, et al.
Publicado: (2022)

The FGF Receptor–1 Tyrosine Kinase Domain Regulates Myogenesis but Is Not Sufficient to Stimulate Proliferation
por: Kudla, Arthur J., et al.
Publicado: (1998)

Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells
por: Weisberg, Ellen, et al.
Publicado: (2013)

Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis
por: Matye, David J., et al.
Publicado: (2021)

Use of FGF-2 and FGF-18 to direct bone marrow stromal stem cells to chondrogenic and osteogenic lineages
por: Shu, Cindy, et al.
Publicado: (2016)

Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer
por: Paller, Channing J, et al.
Publicado: (2014)

Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer
por: De Velasco, Marco A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u5p2q7qi6sis2on70mtb0mki75